1 Metric Ton	FOB Price:USD 11000.0000 -12000.0000

Min.Order :1 Metric Ton
Purity: 99%
Payment Terms : L/C,T/T,MoneyGram

Keywords

Semaglutide 910463-68-2 910463-68-2 Semaglutide

Quick Details

Appearance:white powder
Application:curing agent
PackAge:carton box
ProductionCapacity:1000000|Kilogram|Month
Storage:cool and dry
Transportation:by air by sea or by express

Superiority:

Product quality:

Our company have high quality product , and also the product we have good manufacture .

First of all, this product is of fine quality. Every finish should be checked by quality inspection system.And every one should be also tried out for one month.Besides，this type has a good viscosity. the prouct can make Gel hand sanitizer thickener cosmetics industry.

We can ensure the product quality , If the product is not satisfactory, you can return it at any time.

Price

our product have resonable price and good service high quality and inexpensive, you deserve.every webiste we have the sales point, your purchase is convenient.

Service

Any time on line , from 0.00-24:00 . if you have any questions , pls contact with me ,As long as you have the need, we will serve you wholeheartedly

Details:

Product information

Product Name:	Semaglutide
Synonyms:	Sermaglutide;Semaglutide impurity;Sermaglutide USP/EP/BP;semaglutide;Sermaglutide CAS 910463 68 2;Ozempic, Rybelsus;Ozempic;Semaglutide (H-7894.0001)
CAS:	910463-68-2
MF:	C187H291N45O59
MW:	4113.57754
EINECS:	203-405-2
Product Categories:	GLP;PP;APIs;API;910463-68-2
Mol File:	910463-68-2.mol

Description	Semaglutide, sold under the brand name Ozempic among others, is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management. Semaglutide acts like human glucagon-like peptide-1 (GLP-1) such that it increases insulin secretion, thereby increasing sugar metabolism. It is distributed as a metered subcutaneous injection in a prefilled pen, or as an oral form. One of its advantages over other antidiabetic drugs is that it has a long duration of action, thus, only once-a-week injection is sufficient.
Uses	Semaglutide injection (Wegovy) is used along with an individualized low-calorie, low-fat diet and exercise program to help with weight loss in overweight adults who may also have high blood pressure, diabetes, or high cholesterol. Semaglutide injection is in a class of medications called incretin mimetics. It works by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. Semaglutide injection also works by slowing the movement of food through the stomach and may decrease appetite and cause weight loss.
Definition	ChEBI: Semaglutide is a polypeptide that contains a linear sequence of 31 amino acids joined together by peptide linkages. It is an agonist of glucagon-like peptide-1 receptors (GLP-1 AR) and used for the treatment of type 2 diabetes. It has a role as a hypoglycemic agent, a glucagon-like peptide-1 receptor agonist, an anti-obesity agent, a neuroprotective agent and an appetite depressant. It is a polypeptide and a lipopeptide.
Biological Activity	Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Mechanism of action	Semaglutide is a glucagon-like peptide-1 receptor agonist. It increases the production of insulin, a hormone that lowers the blood sugar level. It also appears to enhance growth of β cells in the pancreas, which are the sites of insulin production. It also inhibits glucagon, which is a hormone that increases blood sugar. It additionally reduces food intake by lowering appetite and slows down digestion in the stomach. In this way it reduces body fat.
Side effects	Side effects including nausea, vomiting, diarrhea, abdominal pain, and constipation may occur. In people with heart problems, it can cause damage to the back of the eye (retinopathy). Side effects include kidney problems, diabetic retinopathy, allergic reactions, low blood sugar, and pancreatitis.
in vitro	Semaglutide is selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) is three-fold decreased compared to liraglutide, whereas the albumin affinity is increased.
in vivo	The plasma half-life is 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs.